To evaluate the impact of detrusor muscle (DM) absence on oncological outcomes in patients with pTaHG within a large, multicenter cohort.
This is a retrospective multicenter study based on a national database including 12 international expert centers.
All patients who underwent transurethral resection of bladder tumor (TURBT) for a new diagnosis of pTaHG bladder cancer between January 2010 and December 2018 were included and divided into two groups according to the presence or absence of DM. Kaplan-Meier curves were used to illustrate survival outcomes, while Cox regression analyses were conducted to identify independent predictors of survival.
Overall, 418 patients had either pTaHG with DM (n = 365;87.3%) or without DM (n = 53;12.7%). After a median follow-up of 30 months, IQR [15;55], the 5-year RFS (40% vs. 50%; p = 0.2) and the 5-year PFS (75% vs. 86%; p = 0.2) were similar between both groups. Cox-regression analysis confirmed that absence of DM was not significantly associated with RFS (HR = 0.68; 95%CI= [0.41-1.15]; p = 0.15) and PFS (HR = 0.68; 95%CI= [0.27-1.69]; p = 0.40). Among 53 patients without DM, 29 (54.7%) underwent a second-look TURBT, with no impact on 5-year RFS (p = 0.1) and 5-year PFS (p = 0.07). Additionally, Cox-regression analysis confirmed that the absence of second-look was not associated with RFS (HR = 0.28; 95%CI= [0.09-0.93]; p = 0.04) and PFS (HR = 0.05; 95%CI= [0.00-0.89]; p = 0.04).
Absence of DM on pathological specimen of pTaHG tumors had no impact on disease recurrence or progression occurrence, calling into question the need for routine second-look procedures for these patients.
World journal of urology. 2025 May 26*** epublish ***
Gabrielle Tissot, Pierre-Etienne Gabriel, Ulysse Dubuet, Sophie Régnier, Idir Ouzaid, Marco Moschini, Francesco Soria, David D'Andrea, Shahrokh F Shariat, Alexandra Budowski, Cédric Poyet, Mathieu Roumiguie, Mario Alvarez Maestro, Alberto Briganti, Wojciech Krajewski, Kees Hendricksen, Hans Veerman, Luca Afferi, Agostino Mattei, Carlo Di Bona, Stefania Zamboni, Claudio Simeone, Ronan Thenault, Gregory Verhoest, Jean-François Hermieu, Evanguelos Xylinas
Department of Urology, Assistance Publique-Hôpitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cité, Paris, France., Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Department of Anesthesiology, University of Zurich, University Hospital Zurich, Zurich, 8091, Switzerland., Department of Urology, University Hospital Zürich, Zürich, Switzerland., Department of Urology, Clinique Pasteur, Toulouse, France., Department of Urology, Hospital Universitario La Paz, Madrid, Spain., Department of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland., Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland., Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy., Department of Urology, Service d'urologie, Rennes University Hospital, Hôpital Pontchaillou, Rennes, France., Department of Urology, Assistance Publique-Hôpitaux de Paris Nord, Bichat Claude-Bernard Hospital, University Paris Cité, Paris, France. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40418371